GLP-1 & compounded medication availability in Nebraska (2026)

Nebraska runs pharmacy oversight through its health department, and it keeps the rulebook general: nothing published singles out GLP-1s or peptide lines. The single Nebraska-specific fact worth checking on a telehealth order is the mail-service license. An out-of-state pharmacy needs one before any dispensed prescription crosses into the state.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Nebraska: all ten lines

Whether each of the ten OrderlyMeds product lines ships to Nebraska, with typical delivery times and notes
Product lineAvailable in Nebraska?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Shipped by partner pharmacies holding Nebraska’s mail-service license.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days National flat pricing; Nebraska included.
NAD+ Yes 8–10 business days Orders flow the same as in every other state.
Sermorelin Yes 8–10 business days No Nebraska-specific condition.
Glutathione No N/A Not part of our formulary at present.
BPC-157 Yes 8–10 business days Injectable line; the federal record is set out below.
TB-500 Yes 8–10 business days Compounded injectable. Federal specifics below.
KPV No N/A Our peptide formulary is injectable-only and does not include this line.
Epitalon Yes 8–10 business days Injectable; read its federal section below.
MOTS-c Yes 8–10 business days Injectable; its federal history is distinct and stated below.

The table shows gaps as gaps. Nebraska rows were last checked on November 16, 2026.

Research peptides in Nebraska: BPC-157, TB-500, KPV, Epitalon & MOTS-c

For Nebraska addresses, OrderlyMeds fills BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables, each on a patient-specific prescription; KPV is not filled anywhere, because we compound these lines as injectables only. The federal record for each line follows, per substance, since the five are not interchangeable, and appears regardless of whether the line ships to you.

BPC-157 in Nebraska

Fills to Nebraska as a compounded injectable on a patient-specific prescription. The two federal facts below travel with it.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Nebraska

A Nebraska-eligible compounded injectable, dispensed on a patient-specific prescription; federal record next.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Nebraska

Not dispensed to Nebraska or any state. Injectable-only peptide formulary; KPV falls outside it.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Nebraska

Ships to Nebraska as a compounded injectable on a patient-specific prescription; the section below is its federal record.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Nebraska

Nebraska-eligible as a compounded injectable on a patient-specific prescription, with a federal record all its own, below.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Nebraska’s pharmacy regulators say about compounded medications

Nebraska’s structure is the story: licensure runs through the Department of Health and Human Services rather than a standalone pharmacy agency, and the requirements it applies to out-of-state pharmacies are general ones, applied to every medication on this page equally.

Under Nebraska’s Mail Service Pharmacy Licensure Act, a pharmacy operating outside Nebraska must obtain a mail service pharmacy license before shipping, mailing, or otherwise delivering dispensed prescription drugs into the state, and must employ at least one full-time licensed pharmacist responsible for its compliance. Source: Nebraska DHHS — out-of-state mail service pharmacy licensure.

Pharmacy licensure in Nebraska is administered by the Department of Health and Human Services under the Uniform Credentialing Act; no GLP-1-specific or peptide-specific compounding guidance has been published. Source: Nebraska Department of Health & Human Services.

Nebraska permits prescriptions issued on the basis of a telehealth encounter meeting the standard of care; no in-person-first requirement applies to the medication lines on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

A Nebraska order follows the standard path: online eligibility, a telehealth evaluation by a Nebraska-licensed provider, and fulfillment by a licensed partner pharmacy holding the mail-service license above. Omaha pays the same national price as every other city.

Nebraska availability FAQs

Does compounded semaglutide ship to Nebraska?

Yes, from licensed partner pharmacies holding Nebraska’s mail-service license, starting at $74/month for the first two months.

What credential should a pharmacy shipping into Nebraska hold?

A Nebraska mail service pharmacy license from DHHS. The cited regulator section above states the requirement and its source.

Which research peptides are available to Nebraska patients?

BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables on patient-specific prescriptions; KPV is not in the formulary. Each line’s own federal record appears above.

How long does Nebraska delivery take?

8–10 business days from signup, per our published window.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone